Keros Therapeutics, Inc.

Total Valuation

Keros Therapeutics, Inc. carries a market capitalization of 335.98M, placing it among publicly traded companies globally. Its enterprise value stands at 88.27M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Keros Therapeutics, Inc. currently has 19.73M shares outstanding.

Valuation Ratios

Keros Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 46.95. The price-to-sales ratio is 10.65, and the price-to-book ratio stands at -0.70.

Enterprise Valuation

On an enterprise value basis, Keros Therapeutics, Inc. trades at an EV/EBITDA multiple of 4.10 and an EV/FCF ratio of 2.61. The EV/Sales ratio of 2.66 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 4.19 provides insight into valuation relative to core operating earnings.

Financial Position

Keros Therapeutics, Inc. maintains a current ratio of 22.62, meaning it holds 22.6x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Stock Price Statistics

Keros Therapeutics, Inc.'s stock has declined approximately -29.1498% over the past 52 weeks. The 50-day moving average sits at 11.37, while the 200-day moving average is 15.25.

Income Statement

Over the trailing twelve months, Keros Therapeutics, Inc. generated 33.18M in revenue and converted that into -85.14M in net income, yielding earnings per share of -2.66. EBITDA reached -108.78M, while operating income came in at -110.35M.

Balance Sheet

Keros Therapeutics, Inc. holds 281.50M in cash and equivalents against 16.31M in total debt, resulting in a net debt position of -281.50M. Total book value stands at -505.47M, with working capital of 277.82M providing operational flexibility.

Cash Flow

Keros Therapeutics, Inc. produced -57.19M in operating cash flow over the past twelve months. After subtracting -1.06M in capital expenditures, free cash flow totaled -58.25M - equivalent to -1.82 per share.

Margins

Keros Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -332.55 and net profit margin of -256.60 provide insight into operational efficiency.

Dividends & Yields

Scores

Keros Therapeutics, Inc. posts an Altman Z-Score of 5.70, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.